Articles

Drug discovery with fewer downstream problems

Cresset and Inocardia to develop in-silico cardiac safety assay for drug candidate screening
Brought to you byDDNews Staff
| 1 min read

CAMBRIDGE, U.K.—Cardiac complications and side effects have traditionally been one of the major areas that cause otherwise promising therapeutic candidates to fail late in the drug development process, so anticipating and heading off this problem at the discovery and preclinical stages is crucial.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.